New regulatory, signaling pathways, and sources of nitric oxide.
Discovered in 1980 by the late Robert F. Furchgott, endothelium-derived relaxing factor, nitric oxide (NO), has been in the forefront of vascular research for several decades. What was originally a narrow approach, has been significantly widened due to major advances in understanding the chemical and biological properties of NO as well as its signaling pathways and discovering new sources of this notorious free radical gas. In this review, recent discoveries regarding NO and their implications on therapy for delayed cerebral vasospasm are presented.
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Room 3D20, Bethesda, MD 20892-1414, USA. Ryszard.Pluta@jama-archives.org
Ryszard M
RM
Pluta
D000818:Animals; D006801:Humans; D008954:Models, Biological; D009566:Nitrates / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism* / Q000627:therapeutic use*; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D020301:Vasospasm, Intracranial / Q000188:drug therapy / Q000201:enzymology*
D009566:Nitrates; D009569:Nitric Oxide; D052248:Nitric Oxide Synthase Type I